|Table of Contents|

A Meta-analysis on effectiveness of EGFR-TKIs compared with chemotherapy as first-line treatment of EGFR mutation-selected non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 04
Page:
566-571
Research Field:
Publishing date:

Info

Title:
A Meta-analysis on effectiveness of EGFR-TKIs compared with chemotherapy as first-line treatment of EGFR mutation-selected non-small cell lung cancer
Author(s):
Tian Chunqin1; 2; Zhao Xinhan1; Geng Huisheng3; Cui Lichun2; Wang Xuan2; Du Jianfei2
1.Oncology Department,First Affiliated Hospital of Xi'an Jiaotong University，Shaanxi Xi'an 710061,China；2.Oncology Department;3.Radiotherapy Centre,the International Cooperation Chang'an Hospital， Shaanxi Xi'an 710016，China.
Keywords:
epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI); non-small cell lung cancer(NSCLC); chemotherapy; randomized controlled trial(RCT)
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.04.017
Abstract:
Objective:To analyze the effectiveness of EGFR-TKIs compared with chemotherapy as first-line on the EGFR mutation-selected patients with non-small cell lung cancer(NSCLC).Methods:Randomized controlled trials(RCT) evaluating the effectiveness of EGFR-TKIs compared with chemotherapy as first line treatment of the EGFR mutation-selected NSCLC were obtained from PubMed,the Cochrane Library and Embase.All literatures were assessed by the inclusion and exclusion criteria,quality assessment and data abstraction.The Meta-analysis was performed by RevMan 5.3.5（Cochrane Collaboration) and STATA 12.0（STATA Corp,College station,TX) software and was contrasted in EGFR-TKIs-treatment of the EGFR mutation-selected NSCLC patients curative effect.The stability and reliability were evaluated by sensitivity analysis and publication bias analysis.Results:A total of 5 trials with 1 091 patients were included in the Meta-analysis.Compared with the chemotherapy group,EGFR-TKI as first-line therapy group in EGFR mutation-selected advanced NSCLC patients showed a higher ORR and PFS,but the OS did not significantly differ.Conclusion:Compared with chemotherapy,EGFR mutation-selected advanced NSCLC patients received more benefits from EGFR-TKIs as first-line treatment.

References:

[1]Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR［J］.N Engl J Med,2010,362(25):2380-2388.
[2]Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or caboplatin-paclitaxel in non-small cell lung cancer［J］.N Engl J Med,2009,361(10):947-957.
[3]Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL,CTONG-0802):A multicentre,open-label,randomised,phase 3 study［J］.Lancet Oncol,2011,12（8):735-742.
[4]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations（LUX-Lung 6):An open-label,randomised phase 3 trial［J］.Lancet Oncol,2014,15（2):213-222.
[5]Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC):A multicentre,open-label,randomised phase 3 trial［J］.Lancet Oncol,2012,13（3):239-246.
[6]Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405):An open label,randomised phase 3 trial［J］.Lancet Oncol,2010,11（2):121-128.
[7]Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia（IPASS)［J］.J Clin Oncol,2011,29(21):2866-2874.
[8]Zhou CC.Overall survival（OS) results from OPTIMAL（CTONG 0802),a phase Ⅲ trial of erlotinib（E) versus carboplatin plus gemcitabine（GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer（NSCLC)［J］.J Clin Oncol,2012,30(suppl):7520.
[9]Yun CH,Boggon TJ,Li Y,et al.Structures of lung cancer-derived EGFR mutants and inhibitor complexes:Mechanism of activation and insights into differential inhibitor sensitivity［J］.Cancer Cell,2007,11(3):217-227.
[10]Chiu CH,Yang CT,Shih JY,et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations［J］.J Thorac Oncol,2015,10(5):793-799.
[11]Meng Miao.The effecacy of icotinib on the treatment of advanced non-small cell lung cancer［J］.China Practical Med，2016,11(20):166-167. ［孟苗.埃克替尼治疗晚期非小细胞肺癌的疗效观察［J］.中国实用医药,2016,11(20):166-167.］
[12]Mitsudomi T,Morita S,YatabeY,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405):An open label,randomised phase 3 trial［J］.Lancet Oncol,2010,11(2):121-128.
[13]Paz-Ares L，Soulières D，Moecks J.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC［J］.J Cell Mol Med,2014,18(8):1519-1539.

Memo

Memo:
-
Last Update: 2016-12-29